Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00046254 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,127
- Enrollment target
NCT00046254: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00046254 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,127 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (176% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00046254, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,127 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
Interventions
- DRUG Zoledronic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,127 participants |
| Start Date | 2002-02 |
| Est. Completion | 2007-02 |
| Phase | Phase 3 |
What the finished NCT00046254 record still lists
NCT00046254 is an interventional study that assigns participants to a tested intervention. Its 2,127 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (176% higher).
The record links to 0 conditions, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT00046254 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00046254 about?
NCT00046254 is a clinical study titled "Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture". The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.
What is the current status of trial NCT00046254?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,127 participants. The study started on 2002-02. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00046254?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT00046254?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00046254's enrollment target sits among peer trials
2,127 98th of 2000 higher than 1,903 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia